Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.
Moderna (NASDAQ: MRNA) has been a strong performer for large-cap biotech stocks this year, with its shares increasing by 404% so far and jumping 515% over the past year. The current share price sits at around $148, down from the $176.66 peak earlier in the year following a significant clinical milestone. This recent decline raises questions about whether Moderna's potential for further growth has been exhausted or if there is still room for substantial returns.
When viewed over a longer timespan, Moderna's trajectory appears markedly different. The company has lost nearly 60% of its value since 2019, a decline attributed to the inability to replicate the early pandemic success that propelled the stock to new heights. While Moderna was instrumental in developing one of the leading COVID-19 vaccines, the market became less convinced of the platform's long-term commercial viability beyond the coronavirus crisis and infectious diseases.
The stock's performance highlights a crucial point: while Moderna has been a stellar performer in the short term, the market's skepticism about its future prospects suggests that the upside may be limited. Investors will need to weigh the potential for resurgence in demand for the company's mRNA technology against the current valuation, which appears to have already factored in a significant portion of its upside.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
